The cost of Rinvoq (upadacitinib) varies depending on insurance coverage, pharmacy, and geographic location. Patients may be eligible for savings programs offered by the manufacturer.
How much does Rinvoq typically cost without insurance?
Without insurance, the list price for a 30-day supply of Rinvoq can be several thousand dollars. For example, a 15 mg extended-release tablet can cost over $6,000 for a month's supply [1]. However, actual out-of-pocket costs can be significantly lower with patient assistance programs.
What financial assistance options are available for Rinvoq?
AbbVie, the manufacturer of Rinvoq, offers a Rinvoq Savings Card program. This program can reduce out-of-pocket costs for eligible commercially insured patients. For those with commercial insurance, the savings card may lower the monthly cost to as little as $5 [1]. Eligibility and specific savings amounts depend on individual insurance plans.
How does insurance affect the price of Rinvoq?
Insurance coverage plays a substantial role in the final cost of Rinvoq. Many insurance plans include Rinvoq on their formularies, but co-pays can still be considerable. Patients are advised to check with their insurance provider to understand their specific coverage and out-of-pocket expenses. For those without prescription drug coverage, the full list price applies unless they qualify for other assistance.
When does Rinvoq's patent expire?
Information regarding the specific patent expiry dates for Rinvoq is available through specialized patent databases. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can indicate when generic versions might become available [2].
Who manufactures Rinvoq?
Rinvoq is manufactured by AbbVie [1].
How is Rinvoq administered?
Rinvoq is taken orally once a day [1]. It is available in extended-release tablets and extended-release pills.
What conditions is Rinvoq approved to treat?
Rinvoq is approved for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and ulcerative colitis in adults who have had an inadequate response or intolerance to one or more TNF antagonists [1].
Sources:
1. https://www.rinvoq.com/cost-and-savings
2. https://drugpatentwatch.com/